Alvotech（ALVO）株式概要
アルボーテックは子会社を通じて、世界中の患者のためにバイオシミラー医薬品の開発・製造を行っている。 詳細
ALVO Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alvotech 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$4.27 |
| 52週高値 | US$9.25 |
| 52週安値 | US$2.94 |
| ベータ | 0.18 |
| 1ヶ月の変化 | 33.86% |
| 3ヶ月変化 | 27.84% |
| 1年変化 | -49.47% |
| 3年間の変化 | -55.29% |
| 5年間の変化 | -56.38% |
| IPOからの変化 | -56.21% |
最新ニュース
ナラティブ更新 • Aug 07
ALVO: FDA Inspection Closure And Biosimilar Resubmissions Will Drive Upside
Analysts have reset their view on Alvotech with a lower implied fair value, moving from about $13.83 to $5.75, as they factor in slightly different assumptions on growth, profitability, and future P/E levels. What’s in the News for Alvotech Alvotech reported that the FDA has closed its May 2026 inspection of the Reykjavik manufacturing facility with a Voluntary Action Indicated classification, following actions taken by the company to address all observations.
ナラティブ更新 • Jul 24
ALVO: Regulatory Progress And Capital Raises Will Support Future Upside
Analysts have reset their 12 month price target on Alvotech from $50.00 to $9.50, citing updated assumptions for long term revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What’s in the News for Alvotech Closed an amended private placement on July 1, 2026, raising total gross proceeds of US$175 million, including participation from funds managed by GoldenTree Asset Management LP and other existing lenders.ナラティブ更新 • Jul 07
ALVO: Biosimilar Advances And Fresh Capital Raises Will Drive Future Upside
Analysts have revised their price target on Alvotech to $50.00, citing updated assumptions for revenue growth, profit margins, and a lower discount rate, which also leads to a reduced future P/E multiple in their models. What’s in the News for Alvotech Alvotech completed a series of capital raises, including a $125 million public offering and related transactions, with some analysts suggesting the stock may appear undervalued based on certain valuation measures, source: Alvotech stock offering coverage.Recent updates
ナラティブ更新 • Aug 07
ALVO: FDA Inspection Closure And Biosimilar Resubmissions Will Drive Upside
Analysts have reset their view on Alvotech with a lower implied fair value, moving from about $13.83 to $5.75, as they factor in slightly different assumptions on growth, profitability, and future P/E levels. What’s in the News for Alvotech Alvotech reported that the FDA has closed its May 2026 inspection of the Reykjavik manufacturing facility with a Voluntary Action Indicated classification, following actions taken by the company to address all observations.ナラティブ更新 • Jul 24
ALVO: Regulatory Progress And Capital Raises Will Support Future Upside
Analysts have reset their 12 month price target on Alvotech from $50.00 to $9.50, citing updated assumptions for long term revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What’s in the News for Alvotech Closed an amended private placement on July 1, 2026, raising total gross proceeds of US$175 million, including participation from funds managed by GoldenTree Asset Management LP and other existing lenders.ナラティブ更新 • Jul 07
ALVO: Biosimilar Advances And Fresh Capital Raises Will Drive Future Upside
Analysts have revised their price target on Alvotech to $50.00, citing updated assumptions for revenue growth, profit margins, and a lower discount rate, which also leads to a reduced future P/E multiple in their models. What’s in the News for Alvotech Alvotech completed a series of capital raises, including a $125 million public offering and related transactions, with some analysts suggesting the stock may appear undervalued based on certain valuation measures, source: Alvotech stock offering coverage.
ナラティブ更新 • Jun 23
ALVO: 2026 Guidance Balanced By Capital Raise And Regulatory Milestones
Analysts have adjusted their price target on Alvotech to $4.00. The updated view reflects slightly lower discount rate assumptions, a modestly higher revenue growth outlook and profit margin expectations, and a marginally lower future P/E multiple.Seeking Alpha • Jun 08
Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements
Summary Alvotech remains a commercial-stage biosimilar company with real revenue, partners, and a growing global footprint. I believe its main upside potential lies with the resubmission of AVT05 and AVT06 after its recent manufacturing delays in the US. ALVO’s valuation has been punished by regulatory setbacks in its manufacturing facilities. So if those concerns are resolved, the stock could quickly re-rate higher. However, there are also substantial risks related to its cash burn and runway until we see ALVO’s optimistic guidance materialize later this year. In my view, ALVO is a viable speculative "Buy" for investors who believe ALVO will ultimately satisfy the FDA’s CMC requirements. Read the full article on Seeking Alphaナラティブ更新 • Jun 06
ALVO: FDA Resubmissions And 2026 Biosimilar Launch Plan Will Drive Upside
Analysts have trimmed their average price target on Alvotech to about $13.83 from $14.00, linking the change to updated views on future P/E assumptions, as well as adjusted expectations for revenue growth and profit margins. Analyst Commentary Recent Street research on Alvotech points to a mixed but focused view on the stock, with several firms adjusting price targets and updating their assumptions around P/E, revenue growth, and margins.ナラティブ更新 • May 19
ALVO: 2026 Revenue Guidance And Pipeline Execution Will Drive Future Upside
Analysts have trimmed their price targets on Alvotech by $1 to $4. This reflects updated views on the company’s growth, profitability, discount rate, and future P/E assumptions.ナラティブ更新 • Apr 29
ALVO: Biosimilar Pipeline And Patent Resolutions Will Support Future Upside
Analysts have reduced their average price target on Alvotech to $46.50, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following recent target cuts from several major banks. Analyst Commentary Recent Street research on Alvotech has centered on recalibrated price targets, with several banks updating their models for valuation drivers such as revenue growth assumptions, margin profiles and target P/E multiples.ナラティブ更新 • Apr 15
ALVO: Biosimilar Pipeline And Partnerships Will Shape Future Upside Potential
Analysts have reduced their price targets on Alvotech, with the consolidated fair value estimate moving from $5.00 to $4.00 as they factor in more moderate revenue growth, lower profit margin assumptions, a higher discount rate, and a higher future P/E multiple. Analyst Commentary Bearish analysts are aligning around a lower fair value for Alvotech, with recent price target revisions pointing to a more cautious stance on the stock.ナラティブ更新 • Mar 31
ALVO: Executing Biosimilar Pipeline And 2026 Revenue Plan Will Unlock Upside
Analysts have reset their view on Alvotech, trimming the average price target from about $22.17 to $14.00 as they factor in updated assumptions for growth, profitability and a higher future P/E, in line with recent target cuts from Deutsche Bank, Barclays and UBS. Analyst Commentary Recent Street research around the reset in the average price target to about $14.00 centers on how quickly Alvotech can execute on its pipeline and translate that into sustainable profitability, as well as what P/E multiple is appropriate given current visibility.ナラティブ更新 • Mar 17
ALVO: Biosimilar Pipeline Progress And Patent Resolutions Will Support Future Upside
Analysts have adjusted their price target for Alvotech to $64.74 per share. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E, while keeping the overall valuation level unchanged.ナラティブ更新 • Mar 03
ALVO: Patent Resolution And Biosimilar Progress Will Support Future Upside
Analysts have updated their price target on Alvotech to $64.74 from $82.94, reflecting revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Alvotech reported positive top line pharmacokinetic results for AVT80, its biosimilar candidate to Entyvio (vedolizumab), with the PK study meeting all primary endpoints in healthy adults, while biosimilarity has not yet been established by regulators.ナラティブ更新 • Feb 17
ALVO: Biosimilar Progress And New Partnerships Will Shape Balanced Risk Outlook
Analysts have raised their price target on Alvotech to $5.00. This change is supported by slightly higher assumptions for revenue growth, profit margin and future P/E.ナラティブ更新 • Feb 03
ALVO: Rebased UBS View And Patent Resolution Will Support Future Upside
Narrative Update on Alvotech Analysts have reduced their price expectations for Alvotech, with one recent update moving a target to US$10 from US$13, along with lower fair value estimates and more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Even with lower headline price targets, some bullish analysts still see room for upside in Alvotech.ナラティブ更新 • Jan 20
ALVO: FDA Letters And Facility Remediation Will Guide Balanced Risk Outlook
Narrative Update on Alvotech The updated analyst price targets for Alvotech, which now cluster around US$8 to US$10 compared with prior views near US$13 to US$14, reflect analysts factoring in recent FDA complete response letters tied to inspection findings at the Reykjavik facility, while still recognizing the unchanged US$5 fair value estimate and broadly similar growth and margin assumptions in the model. Analyst Commentary Recent Street research on Alvotech points to a more cautious tone, with price targets now centered in the US$8 to US$10 range and at least one rating move to Hold after the complete response letter for AVT05 and related inspection findings at the Reykjavik facility.ナラティブ更新 • Jan 05
ALVO: FDA Setbacks And Manufacturing Fixes Will Shape Balanced Risk Profile
Analysts have trimmed their fair value estimate for Alvotech from US$14.00 to US$5.00. This reflects lower price targets on the stock after recent FDA-related setbacks and manufacturing inspection concerns highlighted in recent research updates.ナラティブ更新 • Dec 17
ALVO: Resolution Of FDA Inspection Issues Will Unlock Biosimilar Launch Upside
Analysts have reduced their average price target for Alvotech from about $26.40 to roughly $22.17 per share, citing FDA inspection related uncertainties around key biosimilar launches, as well as a series of recent target cuts and rating downgrades, as justification for a lower, though still constructive, valuation framework. Analyst Commentary Recent Street research reflects a more cautious stance on Alvotech, with several firms cutting price targets and one moving to the sidelines following regulatory setbacks tied to the company’s biosimilar pipeline.ナラティブ更新 • Dec 03
ALVO: Regulatory Resolution Of Manufacturing Issues Will Restore Confidence And Future Upside
Analysts have trimmed their price targets on Alvotech, with cuts of roughly $3 to $6 per share. The reductions reflect increased perceived regulatory risk after recent FDA feedback on key biosimilar programs.分析記事 • Nov 20
Statutory Earnings May Not Be The Best Way To Understand Alvotech's (NASDAQ:ALVO) True Position
Even though Alvotech ( NASDAQ:ALVO ) posted strong earnings recently, the stock hasn't reacted in a large way. We...ナラティブ更新 • Nov 19
ALVO: Regulatory Progress Will Drive Renewed Confidence Amid Recent Downgrade
Alvotech's fair value price target saw a significant increase from $16.10 to $26.40, as analysts revised their outlook based on recent research reports and updated fundamentals. Analyst Commentary Recent analyst reports on Alvotech reflect a mix of optimism about the company's long-term potential and caution regarding recent regulatory and operational setbacks.分析記事 • Nov 09
Alvotech's (NASDAQ:ALVO) 31% Dip In Price Shows Sentiment Is Matching Revenues
Alvotech ( NASDAQ:ALVO ) shareholders that were waiting for something to happen have been dealt a blow with a 31% share...分析記事 • Nov 06
Analysts Just Slashed Their Alvotech (NASDAQ:ALVO) EPS Numbers
Market forces rained on the parade of Alvotech ( NASDAQ:ALVO ) shareholders today, when the analysts downgraded their...ナラティブ更新 • Nov 05
ALVO: Facility Improvements Will Drive Recovery Despite Recent Regulatory Setbacks
Alvotech’s analyst price target has decreased from $17.50 to $16.10 per share. This change reflects analyst concerns over FDA feedback and the resulting downgrades after a recent inspection of the company’s manufacturing facility.分析記事 • May 25
Alvotech (NASDAQ:ALVO) Held Back By Insufficient Growth Even After Shares Climb 29%
Those holding Alvotech ( NASDAQ:ALVO ) shares would be relieved that the share price has rebounded 29% in the last...分析記事 • May 15
Alvotech's (NASDAQ:ALVO) Promising Earnings May Rest On Soft Foundations
Unsurprisingly, Alvotech's ( NASDAQ:ALVO ) stock price was strong on the back of its healthy earnings report. However...新しいナラティブ • May 05
Biosimilar Pipeline And R&D Capability Will Open New Markets
Upcoming biosimilar launches and strategic manufacturing expansions might drive substantial revenue and margin growth, leveraging lost biologic patents.分析記事 • Apr 08
Benign Growth For Alvotech (NASDAQ:ALVO) Underpins Stock's 25% Plummet
Unfortunately for some shareholders, the Alvotech ( NASDAQ:ALVO ) share price has dived 25% in the last thirty days...Seeking Alpha • Nov 21
Alvotech's Position In The Coming Biosimilar Gold Rush
Summary Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with significant revenue growth and strategic product rollouts, despite a leveraged balance sheet. A diverse pipeline targeting high-value biologics and recent regulatory milestones position Alvotech for significant market impact in the biosimilar sector. While facing risks like competition and partner dependency, Alvotech's strategic focus and operational scalability offer considerable growth potential for long-term investors. Read the full article on Seeking AlphaSeeking Alpha • Aug 26
Alvotech: Steady Progress Offers A Good Chance Of Upside
Summary Alvotech offers exposure to the biosimilar industry at a cheaper price compared to other generic drug manufacturers. The company has successfully commercialized two biosimilar drugs - Stelara and Humira - with more in the pipeline. The company announced Q2 earnings on August 16th, with record revenues of $235.6 million and quarterly EBITDA of $102 million. With revenues of $600 million to $800 million promised in 2025, Alvotech stock stands a good chance of realising upside in the second half of 2024. Read the full article on Seeking Alpha分析記事 • May 28
Bullish: Analysts Just Made A Huge Upgrade To Their Alvotech (NASDAQ:ALVO) Forecasts
Celebrations may be in order for Alvotech ( NASDAQ:ALVO ) shareholders, with the analysts delivering a significant...株主還元
| ALVO | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 5.3% | 5.2% | -2.1% |
| 1Y | -49.5% | 43.5% | 18.8% |
業界別リターン: ALVO過去 1 年間で43.5 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: ALVOは、過去 1 年間で18.8 % のリターンを上げたUS市場を下回りました。
価格変動
| ALVO volatility | |
|---|---|
| ALVO Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: ALVOの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: ALVOの weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2013 | 1,279 | Lisa Graver | www.alvotech.com |
アルボーテックは子会社を通じて、世界中の患者のためにバイオシミラー医薬品の開発・製造を行っている。同社は、自己免疫疾患、眼疾患、骨疾患、癌の治療分野においてバイオシミラー医薬品を提供している。同社は、関節リウマチ、乾癬性関節炎、クローン病、強直性脊椎炎、潰瘍性大腸炎、その他の適応症を含む様々な炎症性疾患を治療するヒュミラの高濃度・低容量アダリムマブ製剤バイオシミラーであるAVT02、乾癬性関節炎、クローン病、潰瘍性大腸炎、尋常性乾癬、その他の適応症を含む様々な炎症性疾患を治療するステララのバイオシミラーであるAVT04を提供しています；新生血管性加齢黄斑変性症、網膜静脈閉塞症後の黄斑浮腫、糖尿病黄斑浮腫、糖尿病網膜症など様々な疾患の治療薬であるEyleaのバイオシミラーであるAVT06、XgevaおよびProliaのバイオシミラーであるAVT03。さらに、関節リウマチ、乾癬性関節炎、潰瘍性大腸炎など、さまざまな炎症性疾患の治療薬として、シンポニーとシンポニー・アリアのバイオシミラーであるAVT05を提供している；AVT16は、中等症から重症の潰瘍性大腸炎および中等症から重症の活動性クローン病の成人患者を対象としたEntyvio製品のバイオシミラー、AVT23は、アレルギー性喘息、慢性自然じんま疹（CSU）、鼻ポリープを対象としたXolairのバイオシミラー、AVT33は、開発初期段階にあるキイトルーダ製品のバイオシミラーです。アルボーテックは2013年に設立され、ルクセンブルクに本社を置いている。
Alvotech 基礎のまとめ
| ALVO 基礎統計学 | |
|---|---|
| 時価総額 | US$1.52b |
| 収益（TTM） | -US$80.73m |
| 売上高(TTM) | US$562.04m |
2.7x
P/Sレシオ-18.9x
PER（株価収益率ALVO は割高か？
公正価値と評価分析を参照収益と収入
| ALVO 損益計算書（TTM） | |
|---|---|
| 収益 | US$0 |
| 売上原価 | US$0 |
| 売上総利益 | US$0 |
| その他の費用 | US$0 |
| 収益 | US$0 |
直近の収益報告
Jun 30, 2026
次回決算日
Nov 11, 2026
| 一株当たり利益（EPS） | -0.23 |
| グロス・マージン | 61.53% |
| 純利益率 | -14.36% |
| 有利子負債／自己資本比率 | -463.9% |
ALVO の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/21 17:22 |
| 終値 | 2026/08/20 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Alvotech 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9
| アナリスト | 機関 |
|---|---|
| Glen Santangelo | Barclays |
| Andrew Baum | Citigroup Inc |
| Peter Verdult | Citigroup Inc |